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A clear association was demonstrated between the use of USOL-D-bac type 3 poliovirus live-attenuated vaccine and the
1968 poliomyelitis epidemic in Poland. The epidemic followed small-scale trials with Sabin and USOL-D-bac type 3 vaccine
strains carried out in seven countries including Poland. Factors that might have contributed to the genesis and development
of the epidemic were the pattern of virus excretion from vaccinees, mutations found in viruses from the epidemic, and the
particular vaccination policies in Poland during the previous years. These findings may provide essential insights into the
strategies for stopping polio immunisation once wild poliovirus has been eradicated. © 2000 Academic PressIntroduction. The use of live-attenuated and inacti-
vated poliovirus vaccines will most surely complete the
eradication of paralytic poliomyelitis and circulation of
wild poliovirus from the world in the not too distant future
(3). This will eventually lead to the obvious need to stop
polio vaccination, particularly with live-attenuated vac-
cine strains (20). However, some issues regarding the
scientific basis on how and when to stop polio immuni-
sation are still not satisfactorily answered (3, 20). One of
the most important questions is whether vaccine-derived
isolates, which would be the last strains of poliovirus to
subsist, would survive for long periods in the human
population and/or in the environment and would be able
to infect nonimmune children in the postvaccination era,
reinitiating poliomyelitis epidemics (6). Live-attenuated
vaccine strains replicate in the gut of vaccinees, often
giving rise to poliovirus isolates of increased neuroviru-
lence that are excreted to the environment (15). Vaccine-
associated paralytic poliomyelitis (VAPP) is very rare (;1
case per 2.5 million doses of Sabin oral poliovirus vac-
cine) but, in contacts of vaccinees, VAPP affects mostly
unvaccinated or inadequately vaccinated individuals
(18). Also of great concern is the identification of several
cases of long-term excretion of vaccine-derived poliovi-
rus by individuals with antibody deficiencies (3, 6, 11, 13).
Very little is known, however, about the molecular and
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42genetic basis of poliovirus transmissibility and whether
vaccine-derived strains revert to wild poliovirus transmis-
sibility during person-to-person transmission. Experi-
mental data suggest that vaccine viruses are less trans-
missible than wild strains but also indicate that vaccine-
derived viruses can spread widely under conditions of
low population immunity (6). Importantly, no poliomyelitis
epidemics of vaccine-derived viruses have been re-
ported since the use of Sabin live-attenuated vaccines
became routine in the early 1960s. This is more remark-
able in the case of unvaccinated or poorly vaccinated
groups of individuals within well-vaccinated regions in
which, despite proven exposure to vaccine-derived vi-
ruses, only wild poliovirus strains have been shown to
spread rapidly and cause epidemics. Examples include
religious groups in the United States and Canada, in
which few members accept vaccination, who suffered
epidemics of wild poliovirus type 1 in 1978/1979 and type
3 in 1992/1993, and certain age groups in Albania with
very low vaccination coverage, who suffered an epi-
demic of wild-type 1 poliovirus in 1996 (reviewed in 6). In
this paper we have investigated the possible vaccine
origin of an epidemic of type 3 poliomyelitis in Poland in
1968 (12, 13). The epidemic started after small-scale
trials with Sabin 3 and USOL-D-bac (USOL) live-attenu-
ated vaccine strains had been completed (1). The vac-
cine trials, which also included six other countries, were
carried out to evaluate the USOL strain as an alternative
vaccine to Sabin 3, because of the genetic instability
following replication in humans of Sabin 3 and concerns
about the duration of the immunity induced (1). The
results indicated that the USOL vaccine appeared supe-
rior to the Sabin 3 strain with respect of establishment in
the gut, immunogenicity, and genetic stability (1, 4, 12).
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43RAPID COMMUNICATIONHowever, between March and December 1968, an out-
break of paralytic poliomyelitis associated with type 3
poliovirus with a total of 464 cases was reported in
Poland. The temporal and geographical distribution of
paralytic cases related the outbreak to vaccination of
eight children with the USOL-D-bac live-attenuated strain
in the city of Poznan 4 months before the epidemic
started (1, 12). WHO collaborative studies at the time
ailed to identify the wild or vaccine origin of selected
solates from the epidemic (13). Here, we show experi-
mental evidence that identifies those isolates with the
USOL strain. The properties of the USOL vaccine strain
and isolates from healthy vaccinees and cases from the
epidemic, together with the circumstances in which the
epidemic occurred, were analysed and are discussed in
the light of the strategically difficult decision-making pro-
cess on when and how to stop polio vaccination once
wild poliomyelitis has been eradicated.
Results. Sequence of USOL-D-bac poliovirus vaccine
train. The complete nucleotide sequence of the USOL-
-bac strain (lot 2/66.01.12) used during the 1968 vaccine
rials (1) was determined and analysed to establish the
redicted amino acid sequence. The genome comprises
59 noncoding region (NCR) of 747 nucleotides, a single
open reading frame of 6618 nucleotides (2206 codons), a
short 39 NCR region of 71 nucleotides, and a poly(A) tract.
Table 1 shows the percentage of sequence homology
between the USOL strain and representatives of the
three poliovirus serotypes that have been previously se-
quenced. In agreement with the serotyping, USOL virus
most closely resembled other type 3 strains. This was
clearly evident in the capsid region, which contains the
antigenic determinants and where USOL showed signif-
icantly higher homology with type 3 strains than with type
1 and 2 viruses. However, this was not true in the 59 and
39 noncoding regions and in the region of the genome
coding for nonstructural proteins, where the USOL strain
T
Percentage of Nucleotide and Amino Acid Homology betwe
Strain
Nucleotide
59NCR Capsid
Sabin 1b 83.9 70.5
abin 2c 81.8 71.8
abin 3d 80.1 79.5
3127FIN84e 82.8 84.6
a Nonstructural.
b EMBL Accession No. V01150.
c EMBL Accession No. X00595.
d EMBL Accession No. X00925.
e EMBL Accession No. X04468.showed similar sequence homology to all three poliovi-
rus types (Table 1). As shown in Fig. 1, intratypic phylo-
s
wgenetic analysis using sequence comparison in the
VP1-2A junction region did not show any close associa-
tion of the USOL strain with previously sequenced type 3
strains and found the USOL strain only partially related to
two American isolates from 1986 in Peru (strain 7840)
and Bolivia (strain 7377), which showed only 85.00 and
84.17% sequence homology to the USOL strain, respec-
tively. Amino acid sequences in antigenic sites of the
USOL strain were found to be similar to those in other
type 3 strains from Europe or Mediterranean countries
(16), particularly in isolates from the 1984 poliomyelitis
outbreak in Finland (Table 2). On the contrary, the USOL
strain exhibited marked differences in antigenic struc-
tures with respect to Sabin and Saukett type 3 vaccine
strains with which it shared sequence homology only
through antigenic site 1 (Table 2).
Characterisation of Virus Isolates from Healthy Vacci-
nees and Epidemic Cases. The virus isolates selected for
our study included 7 strains from epidemic cases in Poland,
4 strains from healthy vaccinees, 1 from Poland and 3 from
Hungary, and 1 isolate from a healthy contact of USOL
vaccinees in Romania (see Materials and Methods). The 12
strains were initially characterised by restriction analysis of
RT-PCR products in the 59 NCR. Digestion patterns using
AvaI and BamHI endonucleases identified all isolates from
USOL healthy vaccinees, one of their contacts, and the 7
epidemic cases as USOL-like (data not shown). The iso-
lates were further characterised by nucleotide sequencing.
All 12 isolates were sequenced through the 59 NCR (nucle-
otides ;65–750) covering the major part of the internal
ribosomal entry site (IRES), the coding region (nucleotides
;1150–2040 and ;2420–3380), which included the entire
VP1 capsid protein, all antigenic sites, and part of the
protease 2A sequence, and short fragments at the 39 end of
the nonstructural coding region (nucleotides ;4950–5250
and ;6350–6520), to examine the possibility of genetic
ecombination with other poliovirus strains. The nucleotide
USOL-D-bac Strain and Previously Sequenced Polioviruses
Amino acids
Sa 39NCR Capsid NS
.6 97.0 82.1 96.3
.5 95.4 82.8 96.2
.6 98.5 95.2 96.2
.7 98.5 97.6 95.9ABLE 1
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44 RAPID COMMUNICATIONwere completed in full. Sequence analysis confirmed the
similarity of all isolates with the USOL strain, revealed
several noncoding and coding changes, and eliminated the
occurrence of recombination events with other poliovirus
strains. Figure 1 shows the sequence analysis through the
VP1-2A junction region of epidemic isolates compared to
the USOL strain and previously sequenced type 3 poliovi-
ruses. Mutations found in the 59 NCR and coding regions of
the USOL-derived strains are described in the following
sections.
Nucleotide Changes in the 59 NCR of Virus Isolates.
FIG. 1. UPGMA phylogenetic tree based on the 120-nucleotide sequen
equencing data from wild strains were obtained from Poyry et al. (16
solates 11/52 and 20/92, which contained the least (one) and the most
ighlighted.Few mutations were found in the 59 NCR of the isolates
rom both healthy individuals and paralytic cases with
i
iespect to the USOL strain. Nucleotide transitions were
ound at positions 264 (in all isolates from paralytic
ases); 118, 234, and 385 (in isolate D10/16); 599 (in
solate 5778/67); 620 (in isolates 8/01, 7/61, and 1/6); 625
in isolate 8/01); 629 (in isolates 8/01 and 7/61); 643 (in
solate 20/92); 659 (in isolate 4/22); 668 (in isolate 10/
15); 690 (in isolates 4/22 and 5/91), and 744 (in isolate
/91). Only two of the nucleotide changes were located in
tem structures/regions but none resulted in the disrup-
ion of the predicted secondary structure in the 59 NCR.
he mutation at position 264 (U to C), present in all
he VP1/2A junction region in the genome of 45 type 3 poliovirus strains.
ew et al. (10). The locations of the USOL-D-bac strain and epidemic
nucleotide changes with respect to the USOL strain, respectively, arece of t
) and Ksolates from epidemic cases, results in the strengthen-
ng of a basepair (UzG to C–G) in the predicted secondary
f the 19
c
45RAPID COMMUNICATIONstructure (Fig. 2A) (17). Another U to C mutation at posi-
tion 489 in isolate 5633/67 from a healthy vaccinee re-
sults in the same predicted effect (UzG to C–G).
Amino Acid Mutations in Capsid Proteins of Virus Iso-
lates. Figure 2B shows the location in the Sabin 3 3D-
structure model of the mutations found in capsid resi-
dues of isolates from the epidemic. All isolates from
paralytic cases showed a mutation at VP1-7 from threo-
nine to alanine, at VP1-258 from isoleucine to valine, at
VP1-294 from valine to glutamic acid, and at VP2-191
from alanine to valine. Mutations at positions VP1-294
and VP2-191 were also present in all the USOL-derived
isolates from healthy individuals, including the earliest
isolate, 5633/67, from Hungary, taken only 17 days after
vaccination. Isolates from the epidemic contained a mu-
tation in antigenic site 2a at position VP1-219 from ala-
nine to threonine in isolates 7/61, 8/01, and 1/6 and from
alanine to valine in isolate 4/22. Isolate 8/01 also showed
a change at antigenic site 1 at position VP1-98 from
arginine to lysine. Isolates from healthy individuals con-
tained mutations at antigenic site 2b at VP2-165 from
alanine to threonine in strain 5527/67 and at VP2-166
from valine to alanine in strain 10/715 and at antigenic
site 4 at residue VP3-80 from aspartic acid to asparagine
in isolates 10/715 from Poland, 5527/67 from Hungary,
and D10/16 from Romania, and from aspartic acid to
valine in strain 5778/67 from Hungary.
Amino Acid Mutations in Nonstructural Proteins of
Virus Isolates. The genomes of isolates 11/52 and 1/6
from epidemic cases and strain 10/715 from a healthy
vaccinee in Poland were sequenced completely through
this region. A mutation was found at amino acid 19 (from
T
Comparison of Deduced Amino Acid Sequences at Antigenic Sites b
Virus strain
Site 1
VP1 89-100
Site 2a
VP1 217-223 V
USOL EVDNEQPTTRAQ SDANDNV T
Sabin 3a ------------ T-----I N
Saukettb ------------ T-----I -
21267MOR77b --------S--- nac -
009EGY78b ------------ nac -
20800TUR81b ------------ nac -
1838SPA83b -------A---- ------- -
FIN84d ---------NV- ------- -
a EMBL Accession No. X00925.
b Data from Poyry et al. (16).
c Not available.
d Consensus sequence from the nine isolates from paralytic cases o
ommunication).isoleucine to threonine) of protease 3C in all three iso-
lates. Both epidemic isolates 11/52 and 1/6 containedchanges at amino acid 123 in protease 2A (from isoleu-
cine to valine) and residue 21 in protein 2B (from isoleu-
cine to valine). A mutation at polymerase 3D-133 (from
lysine to arginine) was found only in the first epidemic
strain 11/52, whereas changes at protease 3C-10 (from
methionine to valine) and polymerase 3D-12 (from valine
to methionine) were present only in the latter isolate, 1/6.
Changes at Synonymous Codon Positions in the Cod-
ing Regions of Virus Isolates. The distribution of synon-
ymous nucleotide mutations with respect to the USOL
strain in the region coding for capsid protein VP1 was
analysed in order to investigate the genetic relationships
between the epidemic strains. As shown in Fig. 2C, all
isolates contained a common silent mutation at nucleo-
tide 3127 and different mutations at several other posi-
tions that classified them in two groups. Each of the two
groups was represented by each of the first two isolates,
virus 11/52 from March 25, 1968, and strain 7/61 from
April 20, 1968. All of the other five isolates from epidemic
cases analysed in this study were from June 1968 when
the epidemic was reaching its peak (12). Strains 4/22,
5/91, and 20/92 shared mutations with virus 11/52 at
silent positions 2785 and 2821, whereas isolates 8/01
and 1/6 contained changes at nucleotides 2751, 3193,
and 3297, identical to those found in virus 7/61 (Fig. 2C).
Nucleotide mutations identified at other synonymous
codon positions in the coding region and at noncoding
positions in the hypervariable region of the 59 end were
in good agreement with the suggested genetic relation-
ships between the strains (data not shown). Isolates
10/715 (from a healthy vaccine), 11/52 (from the first
case), and 1/6 (from a later case) contained 0.32, 1.13,
n the USOL-D-bac Strain and Previously Sequenced Type 3 Strains
Antigenic site
b
-172
Site 3a
VP1 286-290
Site 3b
VP3 58-60, 70, 71
Site 4
VP3 77-80
KRE KDGLA ENT VR NLSD
--- RNN-D -S- -T D--Q
--- --N-N -S- -T D--Q
--- ----- --- -- ---E
--- ----- --- -K --K-
--- ----- --- -- ---E
--- ----T -S- -- ----
--- ----- --- -- ----
84 epidemic in Finland. Data from Poyry et al. (16) and Dunn (personalABLE 2
etwee
Site 2
P2 164
AVTSP
-----
-----
-----
-----
-----
-----
-----and 1.59% nucleotide changes at synonymous third-base
codon positions over the entire coding region with re-
t
l
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46 RAPID COMMUNICATIONspect to the USOL vaccine strain, respectively. Taken
together these data generated an estimated rate of evo-
lution of 2.70% mutations at synonymous third-base
codon positions/year, which is remarkably similar to the
sequence evolution rate previously estimated for wild
poliovirus during person-to-person transmission (10) or
for vaccine-derived poliovirus strains during long-term
replication in immunodeficient patients (11, 13). None of
he synonymous mutations identified in epidemic iso-
ates were found in any of the USOL-derived strains from
ealthy individuals including strain 10/715 from a healthy
accinee in Poland.
Discussion. Substantial evidence was obtained that
FIG. 2. Mutations in isolates from the 1968 epidemic with respect to
620 bases of the 59 NCR of poliovirus type 3. The location of the mutati
compared to that of poliovirus strain representatives of the three sero
viewed from the side of the virion (the outside is toward the top left of th
of 60 protomers, each containing a single copy of VP1, VP2, VP3, and VP
are labelled. The equivalent locations of amino acid substitutions iden
cases are underlined; changes found also in isolates from healthy vacc
hydrocarbon-binding pocket is also indicated. (C) Mutations at synony
changes common to two or more isolates is highlighted.elated the 1968 epidemic of type 3 poliomyelitis in Po-
and (1, 12, 13) with the use of live-attenuated USOL-D-ac poliovaccine (19). The temporal and geographical
evidence of the association of the outbreak with a vac-
cine trial in the city of Poznan (1, 12) was confirmed by the
nucleotide sequence analysis of seven isolates from the
epidemic. The nucleotide sequences throughout the ge-
nome of the seven epidemic strains were highly similar
to that of the USOL strain with the exception of a few
mutations that could be assumed to have been incorpo-
rated during replication in vaccinees, their contacts,
and/or patients. Analysis of nucleotide changes at syn-
onymous third-base codon positions, which has been
shown to be an accurate method for measuring poliovi-
rus evolution, was very consistent with the above-men-
OL-D-bac vaccine strain. (A) Predicted secondary structure of the first
ucleotide 264 found in epidemic strains is indicated and the sequence
B) Ribbon diagram of the a-carbon trace of the Sabin 3 protomer (5),
e and the inside is toward the bottom right). The virus particle consists
ged in icosahedral symmetry. The five- and threefold axes of symmetry
epidemic isolates are highlighted. Mutations present in all epidemic
re underlined a single line. The presence of sphingosine (SPH) in the
codon positions in the VP1 coding region. The position of nucleotidethe US
on at n
types. (
e imag
4 arran
tified in
inees ationed vaccine origin of the epidemic. The number of
mutations found in epidemic cases with respect to the
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47RAPID COMMUNICATIONUSOL-D-bac vaccine strain in relation to the time of
vaccination in Poznan and the time of virus isolation from
the patients was remarkably close to that theoretically
expected according to the sequence evolution rate that
has been estimated for poliovirus (10, 11, 13). Not a single
type 3 poliovirus strain had been isolated in Poland
during the 1962–1967 period from poliomyelitis patients
or in virological surveys of healthy persons and sewage
examinations carried out each year (12). There was no
known direct or indirect contact between the cases from
the epidemic selected for this study or between them
and USOL vaccinees or their contacts (1, 13). This obser-
ation highlights the fact that a small vaccine trial was
he origin of such an extensive poliomyelitis outbreak
uring which 464 persons became paralysed and, as-
uming a minimal infection/disease ratio of 200:1 typical
f virulent wild poliovirus strains (20), at least 90,000
eople were infected.
Several factors were considered in order to under-
tand how the epidemic started and developed. First, no
linical symptoms were observed in any of the vacci-
ated children or in their unvaccinated contacts during
2 weeks of careful observations after vaccination in
oland (12). Type 3 viruses were, however, isolated dur-
ng this period from both groups of individuals and there-
ore, it is reasonable to assume that mutations acquired
uring replication in vaccinees or their contacts contrib-
ted to the reversion of the USOL vaccine strain to
ild-type characteristics that prompted the widespread
irculation of the virulent strain(s). As extensively re-
orted before, few mutations seem to be necessary for
he reversion to virulence of the live-attenuated Sabin
accine strains; the mutations in most cases are rapidly
cquired upon replication in the human gut (15). Simi-
arly, few mutations were identified in the 59 NCR and
oding regions of isolates from the 1968 epidemic with
espect to the USOL vaccine strain. All seven isolates
rom paralytic cases contained a mutation at nucleotide
64 (266 in Sabin 3) (from U to C) that results in the
trengthening of a predicted base-pair (GzU to G–C) in
omain IV of the internal ribosomal entry site (Fig. 2A),
hich is conserved in most poliovirus strains (17). How-
ver, none of the USOL-derived isolates from healthy
ndividuals, four vaccinees and one contact, obtained
uring the vaccine trial from Poland and two other dif-
erent countries, carried that nucleotide change. This
bservation suggests that, although mutation at position
64 could confer some biological advantage, it was not
ecessarily selected during replication in the human gut.
n the contrary, mutations at capsid residues VP1-294
nd VP2-191 were present in all isolates from epidemic
ases and healthy individuals from Poland, Hungary, and
omania, including strain 5633/67 taken only 17 days
fter vaccination. VP1-294 is located in the carboxyl-erminal region of VP1 in a position recently shown to be
nvolved in receptor contact in other poliovirus strains (2,
p
t). The relevance of the mutation at residue VP2-191,
ituated in the interior of the capsid monomer inacces-
ible to external and internal surfaces, is unknown. All
even strains from the outbreak, but not those from
ealthy individuals, contained a mutation at residue
P1-7, located in the amino-terminal portion of VP1, a
egion that undergoes dramatic conformational changes
fter virus attachment to susceptible cells that lead to
irus cell entry (7). Amino acid VP1-258, also mutated in
ll epidemic isolates, localizes in the north rim of the
anyon, a surface depression that forms part of the
eceptor footprint (5). Amino acid changes were also
etected at antigenic site 2a in four of the epidemic
solates and at antigenic site 1 only in isolate 8/01. Much
ess is known of the structural and functional signifi-
ance of mutations in nonstructural proteins in relation to
oliovirus attenuation, but mutations were identified at
esidues 2A-123, 2B-21, 3C-10, 3C-19, 3D-12, and 3D-133
n isolates from epidemic cases, from which only muta-
ion at 3C-19 was also present in isolate 10/715 from a
ealthy vaccinee in Poland. The distribution of nucleotide
utations at synonymous codon positions among the
pidemic isolates indicated that all seven strains had a
ommon ancestor and identified two different genotypic
ineages that were cocirculating when the epidemic was
eaching its peak.
It is also important to note that the outbreak was
estricted exclusively to Poland. No similar epidemic
vents were reported in any of the countries that were
ncluded in the same vaccine trial, although in two coun-
ries, Romania (four cases) and USSR (one case), para-
ytic cases occurred in contacts of children immunised
ith the USOL-D-bac strain. Isolation of poliovirus
trains of different serotypes and other enteroviruses
rom those areas at the same time made the determina-
ion of the aetiology of the paralytic cases very complex
1). A possible explanation for epidemic cases to have
ccurred only in Poland lies in the fact that regular
accination programmes in that country differed from
hose in most other countries in that only type 1 and type
strains were included in the live vaccine from 1961.
rom that time, the type 3 component was given exclu-
ively as inactivated vaccine (IPV), which resulted in low
eneral immunity against type 3 poliovirus (12). This
bservation was supported by the atypical age distribu-
ion of epidemic cases that included a higher than usual
roportion of children between 4 and 8 years of age,
ost of whom had been vaccinated with type 3 IPV (12).
he significant differences between the antigenic struc-
ures of the USOL strain and the IPV virus, the Saukett
train (Table 2), suggest that failure to specifically neu-
ralise the epidemic strain as well as low immunity may
ave played an important part in the emergence and
stablishment of the outbreak. Interestingly, a similar
henomenon was described during the 1984 outbreak of
ype 3 poliomyelitis in Finland (9), where polio immuni-
48 RAPID COMMUNICATIONsation has been based exclusively on IPV strains since
1957. The USOL and Finland strains, although not geno-
typically close (Table 1), showed striking similarities in
their antigenic structures (Table 2). Following the same
reasoning, isolates from vaccinees given Sabin 3 virus,
which is more antigenically similar to the Saukett IPV
strain, would have had less potential to cause poliomy-
elitis among the IPV-vaccinated Polish population at the
time of the 1968 epidemic.
Other factors such as the level of viral transmissibility
and/or virulence could explain the fact that vaccination
with Sabin 3 in Poland during the 1968 trials and vacci-
nation with the Sabin strains in general has not been
found to be connected with poliomyelitis outbreaks. Little
is known about the molecular basis of poliovirus trans-
missibility, but duration and titers of virus excretion by
infected individuals are assumed to be important as-
pects that determine the ability of a virus to spread to
other hosts (6). Studies during this and previous vaccine
trials suggested that, although the USOL vaccine ap-
peared to be similar or better than the Sabin 3 strain in
terms of their attenuation properties, immunogenicity,
and genetic stability, USOL vaccinees excreted higher
titers of virus for longer periods of time after vaccination
than children given Sabin 3 vaccine (1, 4, 12). This pattern
of virus excretion could have been an essential factor
that triggered the widespread circulation of the revertant
strain(s) from USOL vaccinees or their contacts that
eventually led to the establishment of the outbreak.
Considered together, the above data strongly suggest
that USOL-D-bac-like strains derived from the vaccine
trial in Poznan were responsible for most, if not all, of the
paralytic cases during the 1968 epidemic. However, only
a small proportion of cases were analysed (less than 2%
of the total) and therefore, the possibility of other type 3
poliovirus strains of different origin being responsible for
paralytic cases cannot be completely ruled out. Efforts
are under way to locate more isolates from the epidemic
and confirm this hypothesis.
The conclusions drawn from this paper raise important
concerns with regard to the design of strategies for
stopping polio vaccination once wild poliomyelitis has
been eradicated (3, 20). Here we describe the first ex-
ample of a widespread epidemic of paralytic poliomyeli-
tis related to vaccine-derived strains, in circumstances
that may occur during the first few years after vaccination
is interrupted. In the light of our observations, long-term
virus excretion from immunodeficient individuals, who
have been shown to excrete polioviruses for periods as
long as 10 years after vaccination (3, 11), may constitute
a serious risk for the reintroduction of poliomyelitis epi-
demics in the postvaccination era. Evaluation and control
of the prevalence of poliovirus infection among immuno-
deficient individuals is therefore essential before a major
decision such as stopping polio immunisation could be
taken.Materials and Methods. USOL-D-bac strain and vac-
cine trial. The USOL-D-bac strain was developed in 1962
from a type 3 poliovirus isolated in 1960 in Czechoslo-
vakia from a paralytic patient (19). The attenuation prop-
erties of the strain were extensively studied before the
1967-1968 vaccine trials including massive vaccine trials
in Czechoslovakia and small-scale trials in Russia and
Switzerland (1, 4, 19). The vaccine batch (lot 2/66.01.12)
used in the 1967-1968 trials was prepared at the Institute
Sieroterapico Milanese (Milan, Italy) and was subjected
to exhaustive quality tests in the National Institute for
Medical Research (London, UK) and the Institute of Po-
liomyelitis and Viral Encephalitis (Moscow, USSR) (1).
Small-scale vaccine trials took place in France, the
United Kingdom, Japan, Romania, Russia, Hungary, and
Poland between September 1967 and March 1968 (de-
scribed in detail in Ref. 1). In Poland there were three
sets of vaccinations. On November 3, 1967, in Poznan
City, eight children were vaccinated with the USOL virus.
On November 15, 1967, in Bialystoc (considerably distant
from Poznan), 10 children were immunised with the
Sabin 3 strain. In addition, on February 16, 1968, nine
children in Slupsk were given the USOL vaccine (1, 12).
Poliomyelitis Outbreak and Virus Isolates Selected for
Analysis. The 1968 epidemic in Poland (described in
detail in Ref. 12) endured from March to December 1968.
More than half of the 464 paralytic cases were reported
in Poznan City and Province and, although the epidemic
spread to other parts of the country, it was restricted
mostly to the northern and western provinces of Poland
surrounding the Poznan Province. The epidemic dimin-
ished in September 1968 following mass vaccinations
with live-attenuated vaccine in August, with only 5 cases
reported in October, 2 in November, and 1 in December
(12). Isolates from paralytic cases available from the
WHO collaborative studies (14) included viruses from the
first two cases, 11/52 (taken on 25 March 1968) and 7/61
(taken on 20 April 1968), and five later isolates from five
other unrelated patients: 8/01 (from June 24, 1968), 4/22
(from June 17, 1968), 1/6 (from June 21, 1968), 5/91 (from
June 19, 1968), and 20/92 (taken on June 25, 1968). Our
analysis also incorporated isolates from USOL healthy
vaccinees: one isolate (10/715) from Poznan City taken at
day 66 after vaccination; three isolates taken from
healthy vaccinees in Hungary, 5633/67 (17 days after
vaccination), 5527/67 (49 days after vaccination), and
5778/67 (77 after vaccination); and one isolate (D10/16)
from a healthy contact of USOL vaccinees in Romania
taken 52 days after vaccination. Isolates were prepared
in primary monkey kidney cells from faecal suspensions
at the National Institute for Medical Research (Hamp-
stead Laboratories, London, UK). Faecal samples from
epidemic cases were collected between 2 and 21 days
after the onset of paralysis (14).
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49RAPID COMMUNICATIONReverse Transcription, PCR, and Nucleotide Sequenc-
ing of Poliovirus Genomes. Poliovirus RNA was purified
from HEp2-c cell culture supernatants and used for re-
verse transcription and PCR using standard procedures.
DNA fragments containing the 59 end of the viral cDNAs
were obtained by the use of the 59/39 RACE kit (Boeh-
ringer) according to the manufacturer’s instructions. Se-
quencing of the purified viral RT-PCR DNA products was
carried out using the ABI Prism 310 Genetic Analyser as
specified by the manufacturer. Primers were designed by
the “primer walking” strategy.
Analysis of Sequence Data. Sequence data were
stored as Standard Chromatogram Format (*.scf) files
and analysed using the Wisconsin Package Version 10.0-
UNIX (GCG) and AlignIRV11 (LI-COR) software. Genetic
relationships between poliovirus strains were estimated
by sequence comparison in the 120-nucleotide VP1/2A
junction region of the genome (positions 3317 to 3436 in
Sabin 3 genome) (10).
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